J&J: positive data in multiple myeloma

(CercleFinance.com) - Johnson & Johnson announces that a Phase 3 study demonstrated that Darzalex Faspro significantly delayed the progression of high-risk indolent multiple myeloma (IMM) to active multiple myeloma (MM), while prolonging overall survival compared with active surveillance.


After a median follow-up of 65.2 months, 63.1% of patients on Darzalex Faspro remained progression-free at 60 months, compared with 40.8% on active surveillance.

Overall survival at 5 years was 93% for Darzalex Faspro versus 86.9% for surveillance (HR 0.52).

These results underline the potential of Darzalex Faspro to delay progression and prevent damage in active multiple myeloma, the study author said.

This data was presented at the ASH 2024 annual meeting.


Copyright (c) 2024 CercleFinance.com. All rights reserved.